Nevro News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.22	Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions (PR Newswire)
04.05.22	Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance (PR Newswire)
06.04.22	Nevro to Report First Quarter 2022 Financial Results (PR Newswire)
07.03.22	Nevro Announces Positive Medicare Coverage Update from Noridian for the Treatment of Painful Diabetic Neuropathy (PR Newswire)
23.02.22	Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance (PR Newswire)
18.02.22	Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series (PR Newswire)
11.02.22	Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine (PR Newswire)
31.01.22	Nevro to Present at Citi's 2022 Virtual Healthcare Conference (PR Newswire)
26.01.22	Nevro Named to 2022 Bloomberg Gender-Equality Index (PR Newswire)
25.01.22	Nevro Responds to Competitor's Announcement of FDA Approval for Painful Diabetic Neuropathy (PR Newswire)
24.01.22	Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results (PR Newswire)
19.01.22	Nevro: FDA Approves Expanded Labeling For 10 KHz Spinal Cord Stimulation System (RTTNews)
19.01.22	Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP) (PR Newswire)
18.01.22	Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy (PR Newswire)
10.01.22	Nevro Corp. Expects To Exceed High End Of Q4 Non-GAAP Adj. EBITDA Guidance - Quick Facts (RTTNews)
10.01.22	Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue (PR Newswire)
04.01.22	Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy (PR Newswire)
21.12.21	Nevro Announces Settlement of IP Litigation with Nalu Medical (PR Newswire)
20.12.21	CORRECTING AND REPLACING -- Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
13.12.21	Nevro Announces Three Podium Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2022 Annual Meeting (PR Newswire)
10.12.21	Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
30.11.21	Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting (PR Newswire)
29.11.21	Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy (PR Newswire)
08.11.21	Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance (PR Newswire)
01.11.21	Nevro Announces Update in Patent Litigation with Boston Scientific (PR Newswire)
25.10.21	Nevro to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (PR Newswire)
11.10.21	Nevro to Report Third Quarter 2021 Financial Results (PR Newswire)
31.08.21	Nevro Announces Director Appointment (PR Newswire)
26.08.21	Nevro to Present at Baird 2021 Global Healthcare Conference (PR Newswire)
25.08.21	Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference (PR Newswire)
04.08.21	Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance (PR Newswire)
26.07.21	EnviroGold Global Provides CEO Updates (PR Newswire)
26.07.21	EnviroGold Global Provides CEO Updates (PR Newswire)
20.07.21	EnviroGold Global annonce d'importants développements stratégiques (PR Newswire)
19.07.21	EnviroGold Global Announces Key Strategic Developments (PR Newswire)
19.07.21	EnviroGold Global Announces Key Strategic Developments (PR Newswire)
19.07.21	Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) (PR Newswire)
16.07.21	Les actions d'EnviroGold Global Limited commenceront à être négociées à la Bourse des valeurs canadiennes (CSE) (PR Newswire)
15.07.21	EnviroGold Global Limited to Commence Trading on the Canadian Securities Exchange (PR Newswire)
15.07.21	EnviroGold Global Limited to Commence Trading on the Canadian Securities Exchange (PR Newswire)
15.07.21	IIROC Trade Resumption - NVRO (PR Newswire)
15.07.21	IIROC Trade Resumption - NVRO (PR Newswire)
07.07.21	Nevro to Report Second Quarter 2021 Financial Results (PR Newswire)
22.06.21	Nevro Announces SENZA-NSRBP Clinical Data Presentation at the American Society of Interventional Pain Physicians 23rd Annual Meeting (PR Newswire)
22.06.21	Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions (PR Newswire)
14.06.21	Nevro to Host Virtual Analyst & Investor Briefing (PR Newswire)
15.12.20	Nevro Reaches Agreement To Conclude Patent Lawsuit In California Against Boston Scientific (RTTNews)
27.01.20	Stock Alert: Nevro Corp. (NVRO) Hits Another High, Up Nearly 12% This Month (RTTNews)
20.03.19	Nevro Stock Up On Appointment Of Keith Grossman As CEO; Suspends FY19 Outlook (RTTNews)
22.02.19	IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Nevro Corp

Aktien Top/Flop

Meistgelesene Nachrichten